Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Probity Medical Research · Dermatologikum Hamburg · +8 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
667
total citations
- FWCI
- 28.47
- Percentile
- 100%
- References
- 16
Citations per year
Authors
12Topics & keywords
Topics
Keywords
- Apremilast
- Medicine
- Psoriasis
- Plaque psoriasis
- Randomized controlled trial
- Dermatology
- Phosphodiesterase inhibitor
- Phosphodiesterase
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- ALAbbott Laboratories
- AAmgen
- ELEli Lilly and Company
- PPfizer
- APAstellas Pharma US
- GGlaxoSmithKline
- MMerck
- NNovartis
- 33M
- BIBiogen Idec
- CCelgene
- AAbbVie
- NINational Institute for Health and Care Research
- GGalderma
- LPLEO Pharma
- GGenentech
- JAJohnson and Johnson
- AAllergan
- MSMerck Sharp and Dohme
- SSandoz
- JPJanssen Pharmaceuticals